SCHEMBL25510624

SCHEMBL25510624

COC(=O)c1scnc1-c1cccc(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORB Q92753 4/20 0.62
SLC6A3 Q01959 4/20 0.48
MAPT P10636 4/20 0.48
KDM4E B2RXH2 3/20 0.48
SLC6A2 P23975 1/20 0.46
HPGD P15428 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
RORC P51449 1/20 0.45
GABRA5 P31644 1/20 0.43
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42
ABL1 P00519 1/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
NPC1 O15118 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4371693 0.78 ALPL (0.49) RORBSLC6A3MAPTKDM4EHPGD
SCHEMBL983944 0.78 SLC6A3 (0.47) RORBSLC6A3KDM4ESLC6A2LMNA
SCHEMBL11002629 0.76 ALDH1A1 (0.49) RORBSLC6A3MAPTKDM4ESLC6A2
SCHEMBL14564441 0.76 ALDH1A1 (0.44) MAPTKDM4EHPGDALDH1A1MAPK1
SCHEMBL17785030 0.74 TRPV1 (0.48) RORBSLC6A3MAPTKDM4ESLC6A2
SCHEMBL15940280 0.73 MAPT (0.56) RORBSLC6A3MAPTKDM4ESLC6A2
SCHEMBL24508639 0.72 JAK2 (0.51) RORBMAPTKDM4EHPGDALDH1A1
SCHEMBL2222523 0.71 GABRA5 (0.52) SLC6A3MAPTKDM4ESLC6A2HPGD
SCHEMBL1937391 0.71 CNR2 (0.59) SLC6A3SLC6A2ALDH1A1L3MBTL1CNR1
SCHEMBL6167654 0.71 CA12 (0.49) ALDH1A1GABRA5NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230147428-A1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT JMACKEM CO., LTD (KR) 2023-05-11 US disclosed
US-20230147428-A1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT JMACKEM CO., LTD (KR) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147428-A1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT TRPV1, TRPA1, TRPV5 RORB 2140/4885SLC6A3 3769/4885MAPT 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.